Nemtabrutinib Clinical Trials
8 recruitingDrug
Phase 24Phase 32Phase 12
Showing 1–8 of 8 trials
Recruiting
Phase 2
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center20 enrolled1 locationNCT07194980
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled196 locationsNCT06136559
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
Healthy
Merck Sharp & Dohme LLC24 enrolled1 locationNCT07232589
Recruiting
Phase 2
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Richter Syndrome
Roswell Park Cancer Institute32 enrolled1 locationNCT06863402
Recruiting
Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 2
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Mantle Cell Lymphoma
City of Hope Medical Center27 enrolled2 locationsNCT06572618
Recruiting
Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Hepatic Impairment (HI)
Merck Sharp & Dohme LLC32 enrolled3 locationsNCT06442436